News

Taipei, Taiwan, October 25, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved the acquisition of US-based Pyros Pharmaceuticals, Inc. (“Pyros”), a specialty pharmaceutical company developing treatments for rare diseases. Founded in 2017 by Michael Smith and Edwin Urrutia, Pyros recently launched VIGAFYDETM...

Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business   TAIPEI, TAIWAN, October 3, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today announced the appointment of J.D. Mowery to the newly created position of Division President of Bora’s CDMO business. “Through our acquisitions and joint...

Taipei, Taiwan - September 4, 2024 - Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the biosimilar-focused biopharmaceutical company and CDMO, today announced that its Board of Directors has appointed Stephen Lam as the Company's Chief Executive Officer, effective September 5, 2024. Stephen succeeds Henry Chen, who shall remain the Chairman until the closing of Tanvex’s...

  Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved a strategic investment into Tanvex Biopharma Co., Ltd. ("Tanvex", TWSE: 6541), whereby Bora Biologics, a wholly owned subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities...